Evolving Paradigms in Newly Diagnosed and R/R MM: Highlights from ASH 2024
home / around-the-practice / evolving-paradigms-in-newly-diagnosed-and-r-r-mm-highlights-from-ash-2024
Panelists discuss how emerging treatment strategies, including novel induction therapies, maintenance regimens, and bispecific antibodies, are reshaping the management of newly diagnosed and relapsed/refractory multiple myeloma, with insights from ASH 2024 data and ongoing trials.
EP. 1: Highlights from ASH 2024: Optimizing Frontline Therapy in Transplant-Eligible MM
Luciano Costa, MD, PhD;Bhagirathbhai Dholaria, MD;Carl Ola Landgren, MD, PhD ;Muhamed Baljevic, MD, FACP
December 17th 2024Panelists discuss recent clinical trial findings, including the PERSEUS, CASSIOPEIA, IsKia, and GMMG-HD7 studies, and how these evolving treatment strategies are shaping the approach to frontline therapy for patients with transplant-eligible multiple myeloma.
